β-Thalassemia remains a significant global health burden, with an estimated 80–90 million carriers worldwide. The highest prevalence of β-thalassemia is observed in the Mediterranean, Middle East, South Asia, and Southeast Asia, where annual births of affected individuals exceed 60,000 [1]. Iron overload represents a detrimental impact in patients with β-thalassemia, arising predominantly from chronic transfusion therapy and ineffective erythropoiesis. The pathological accumulation of iron withi…